Association study of rs1801282 PPARG gene polymorphism and immune cells and cytokine levels in a Spanish pregnant women cohort and their offspring
MetadataShow full item record
AuthorGarcía Ricobaraza, María; García Bermúdez, María Mercedes; Torres Espínola, Francisco J.; Segura Moreno, María Teresa; Campoy Folgoso, Cristina
Pro12Ala PPARG polymorphismImmune systemPregnant mothersNewborn cord blood
García-Ricobaraza, M., García-Bermúdez, M., Torres-Espinola, F. J., Moreno, M. T. S., Bleyere, M. N., Díaz-Prieto, L. E., ... & Campoy, C. (2020). Association study of rs1801282 PPARG gene polymorphism and immune cells and cytokine levels in a Spanish pregnant women cohort and their offspring. Journal of Biomedical Science, 27(1), 1-9. [https://doi.org/10.1186/s12929-020-00694-3]
SponsorshipAndalusian Ministry of Innovation and Science, Junta de Andalucía, Excellence Project P06-CTS-02341; Spanish Ministry of Economy and Competitiveness BFU2012-40254-C03-01; Abbott Laboratories, Granada, Spain
Background: Peroxisome proliferator activated receptor gamma (PPARG ) belongs to the nuclear receptor superfamily functioning as transcription factors to regulate cellular differentiation, development and metabolism. Moreover, it has been implicated in the regulation of lipid metabolism, as well as the maturation of monocytes/macrophages and the control of inflammatory reactions. The aim of this study was to evaluate the relationship between the Pro12Ala (rs1808212) PPARG gene polymorphism on immune molecular and cellular components in mothers and their offspring participating in the PREOBE study. Methods: DNA from maternal venous blood samples at 24, 34 and 40 gestational weeks, plus cord blood samples was extracted. Pro12Ala PPARG polymorphism genotyping was performed, and immune system markers were analyzed by flow cytometry. Results: Study findings revealed no effect of rs1808212 PPARG genotypes on innate immune parameters in mothers and their offspring; however, CD4 + /CD8 + ratio were decreased at 24 and 34 weeks in pregnant women carrying the CG (Pro12Ala) rs1808212 polymorphism, (p = 0,012 and p = 0,030; respectively). Only CD19 levels in peripheral blood were significantly higher at delivery in pregnant women carrying the CC (Pro12Pro) genotype (p ≤ 0.001). Moreover, there were statistically significant differences in leukocytes and neutrophils maternal levels at 34 weeks of gestation, being lower in carriers of Pro12Ala genotype (p = 0.028 and p = 0.031, respectively). Conclusions: Results suggest that Pro12Ala PPARG polymorphism may have an effect on some cell and immune parameters in pregnant women during pregnancy and at time of delivery. However, newborn innate immune system does not seems to be influenced by PPARG Pro12Ala polymorphism in cord blood.